Cargando…
Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis
To evaluate the changes in the gut microbiota associated with changes in the biochemical markers of nonalcoholic fatty liver disease (NAFLD) after a lifestyle intervention with the Mediterranean diet. Participants (n = 297) from two centers of PREDIMED-Plus trial (Prevención con Dieta Mediterránea)...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288930/ https://www.ncbi.nlm.nih.gov/pubmed/37345236 http://dx.doi.org/10.1080/19490976.2023.2223339 |
_version_ | 1785062175834898432 |
---|---|
author | Gómez-Pérez, Ana María Ruiz-Limón, Patricia Salas-Salvadó, Jordi Vioque, Jesús Corella, Dolores Fitó, Montse Vidal, Josep Atzeni, Alessandro Torres-Collado, Laura Álvarez-Sala, Andrea Martínez, María Ángeles Goday, Albert Benaiges, David García-Gavilán, Jesús Bernal López, María Rosa Moreno-Indias, Isabel Tinahones, Francisco J. |
author_facet | Gómez-Pérez, Ana María Ruiz-Limón, Patricia Salas-Salvadó, Jordi Vioque, Jesús Corella, Dolores Fitó, Montse Vidal, Josep Atzeni, Alessandro Torres-Collado, Laura Álvarez-Sala, Andrea Martínez, María Ángeles Goday, Albert Benaiges, David García-Gavilán, Jesús Bernal López, María Rosa Moreno-Indias, Isabel Tinahones, Francisco J. |
author_sort | Gómez-Pérez, Ana María |
collection | PubMed |
description | To evaluate the changes in the gut microbiota associated with changes in the biochemical markers of nonalcoholic fatty liver disease (NAFLD) after a lifestyle intervention with the Mediterranean diet. Participants (n = 297) from two centers of PREDIMED-Plus trial (Prevención con Dieta Mediterránea) were divided into three different groups based on the change tertile in the Hepatic Steatosis Index (HSI) or the Fibrosis−4 score (FIB−4) between baseline and one year of intervention. One-year changes in HSI were: tertile 1 (T1) (−24.9 to −7.51), T2 (−7.5 to −1.86), T3 (−1.85 to 13.64). The most significant differences in gut microbiota within the year of intervention were observed in the T1 and T3. According to the FIB−4, participants were categorized in non-suspected fibrosis (NSF) and with indeterminate or suspected fibrosis (SF). NSF participants showed higher abundances of Alcaligenaceae, Bacteroidaceae, Bifidobacteriaceae, Clostridiaceae, Enterobacteriaceae, Peptostreptococcaceae, Verrucomicrobiaceae compared to those with SF. Then, participants were divided depending on the FIB−4 tertile of change: T1 (−89.60 to −5.57), T2 (−5.56 to 11.4), and T3 (11.41 to 206.24). FIB−4 T1 showed a decrease in Akkermansia and an increase in Desulfovibrio. T2 had an increase in Victivallaceae, Clostridiaceae, and Desulfovibrio. T3 showed a decrease in Enterobacteriaceae, and an increase in Sutterella, Faecalibacterium, and Blautia. A relation between biochemical index changes of NAFLD/NASH (HSI and FIB−4) and gut microbiota changes were found. These observations highlight the importance of lifestyle intervention in the modulation of gut microbiota and the management of metabolic syndrome and its hepatic manifestations. |
format | Online Article Text |
id | pubmed-10288930 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-102889302023-06-24 Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis Gómez-Pérez, Ana María Ruiz-Limón, Patricia Salas-Salvadó, Jordi Vioque, Jesús Corella, Dolores Fitó, Montse Vidal, Josep Atzeni, Alessandro Torres-Collado, Laura Álvarez-Sala, Andrea Martínez, María Ángeles Goday, Albert Benaiges, David García-Gavilán, Jesús Bernal López, María Rosa Moreno-Indias, Isabel Tinahones, Francisco J. Gut Microbes Research Paper To evaluate the changes in the gut microbiota associated with changes in the biochemical markers of nonalcoholic fatty liver disease (NAFLD) after a lifestyle intervention with the Mediterranean diet. Participants (n = 297) from two centers of PREDIMED-Plus trial (Prevención con Dieta Mediterránea) were divided into three different groups based on the change tertile in the Hepatic Steatosis Index (HSI) or the Fibrosis−4 score (FIB−4) between baseline and one year of intervention. One-year changes in HSI were: tertile 1 (T1) (−24.9 to −7.51), T2 (−7.5 to −1.86), T3 (−1.85 to 13.64). The most significant differences in gut microbiota within the year of intervention were observed in the T1 and T3. According to the FIB−4, participants were categorized in non-suspected fibrosis (NSF) and with indeterminate or suspected fibrosis (SF). NSF participants showed higher abundances of Alcaligenaceae, Bacteroidaceae, Bifidobacteriaceae, Clostridiaceae, Enterobacteriaceae, Peptostreptococcaceae, Verrucomicrobiaceae compared to those with SF. Then, participants were divided depending on the FIB−4 tertile of change: T1 (−89.60 to −5.57), T2 (−5.56 to 11.4), and T3 (11.41 to 206.24). FIB−4 T1 showed a decrease in Akkermansia and an increase in Desulfovibrio. T2 had an increase in Victivallaceae, Clostridiaceae, and Desulfovibrio. T3 showed a decrease in Enterobacteriaceae, and an increase in Sutterella, Faecalibacterium, and Blautia. A relation between biochemical index changes of NAFLD/NASH (HSI and FIB−4) and gut microbiota changes were found. These observations highlight the importance of lifestyle intervention in the modulation of gut microbiota and the management of metabolic syndrome and its hepatic manifestations. Taylor & Francis 2023-06-21 /pmc/articles/PMC10288930/ /pubmed/37345236 http://dx.doi.org/10.1080/19490976.2023.2223339 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
spellingShingle | Research Paper Gómez-Pérez, Ana María Ruiz-Limón, Patricia Salas-Salvadó, Jordi Vioque, Jesús Corella, Dolores Fitó, Montse Vidal, Josep Atzeni, Alessandro Torres-Collado, Laura Álvarez-Sala, Andrea Martínez, María Ángeles Goday, Albert Benaiges, David García-Gavilán, Jesús Bernal López, María Rosa Moreno-Indias, Isabel Tinahones, Francisco J. Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis |
title | Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis |
title_full | Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis |
title_fullStr | Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis |
title_full_unstemmed | Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis |
title_short | Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis |
title_sort | gut microbiota in nonalcoholic fatty liver disease: a predimed-plus trial sub analysis |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288930/ https://www.ncbi.nlm.nih.gov/pubmed/37345236 http://dx.doi.org/10.1080/19490976.2023.2223339 |
work_keys_str_mv | AT gomezperezanamaria gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis AT ruizlimonpatricia gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis AT salassalvadojordi gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis AT vioquejesus gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis AT corelladolores gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis AT fitomontse gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis AT vidaljosep gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis AT atzenialessandro gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis AT torrescolladolaura gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis AT alvarezsalaandrea gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis AT martinezmariaangeles gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis AT godayalbert gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis AT benaigesdavid gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis AT garciagavilanjesus gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis AT bernallopezmariarosa gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis AT morenoindiasisabel gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis AT tinahonesfranciscoj gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis |